Skip to content

Study · Randomized controlled trial · n = 15 · 2010

4 results

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.

Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A

Biological psychiatry7 Jul 2010Cited by 243 (Europe PMC)

PMID20615494 (opens in a new tab)DOI10.1016/j.biopsych.2010.04.039 (opens in a new tab)PepBankPUB-20615494
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with schizophrenia and residual symptoms on antipsychotics, adjunctive intranasal oxytocin reduced Positive and Negative Symptom Scale scores versus placebo at the 3-week end point.

    In plain wordsIn adults with schizophrenia, nose-spray oxytocin added to antipsychotics lowered symptom scores more than placebo after 3 weeks.

    Peptide
    Oxytocin
    Outcome
    DecreasePositive and Negative Symptom Scale score at 3 weeks
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    titrated to 40 IU twice a day · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Analysis of the 15 subjects who completed all the study visits revealed that oxytocin significantly reduced scores on the Positive and Negative Symptom Scale (p < .001) and Clinical Global Impression-Improvement Scale (p < .001) compared with placebo at the 3-week end point.
    2 context sentences
    Summary · context
    Nineteen schizophrenia patients with residual symptoms despite being on a stable dose of at least one antipsychotic were enrolled in a randomized, double-blind, crossover study.
    Summary · context
    They received 3 weeks of daily intranasal oxytocin (titrated to 40 IU twice a day) and placebo adjunctive to their antipsychotics.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with schizophrenia and residual symptoms on antipsychotics, adjunctive intranasal oxytocin reduced Clinical Global Impression-Improvement scores versus placebo at the 3-week end point.

    In plain wordsIn adults with schizophrenia, nose-spray oxytocin added to antipsychotics gave better clinician-rated improvement scores than placebo after 3 weeks.

    Peptide
    Oxytocin
    Outcome
    DecreaseClinical Global Impression-Improvement score at 3 weeks
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    titrated to 40 IU twice a day · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Analysis of the 15 subjects who completed all the study visits revealed that oxytocin significantly reduced scores on the Positive and Negative Symptom Scale (p < .001) and Clinical Global Impression-Improvement Scale (p < .001) compared with placebo at the 3-week end point.
    2 context sentences
    Summary · context
    Nineteen schizophrenia patients with residual symptoms despite being on a stable dose of at least one antipsychotic were enrolled in a randomized, double-blind, crossover study.
    Summary · context
    They received 3 weeks of daily intranasal oxytocin (titrated to 40 IU twice a day) and placebo adjunctive to their antipsychotics.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with schizophrenia, intranasal oxytocin showed no benefit over placebo at the early time points.

    In plain wordsIn adults with schizophrenia, nose-spray oxytocin showed no benefit over placebo early in the trial.

    Peptide
    Oxytocin
    Outcome
    No significant changeSymptom scores at early time points
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    titrated to 40 IU twice a day · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    No benefit was seen at the early time points.
    2 context sentences
    Summary · context
    Nineteen schizophrenia patients with residual symptoms despite being on a stable dose of at least one antipsychotic were enrolled in a randomized, double-blind, crossover study.
    Summary · context
    They received 3 weeks of daily intranasal oxytocin (titrated to 40 IU twice a day) and placebo adjunctive to their antipsychotics.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with schizophrenia, intranasal oxytocin was well tolerated and produced no adverse effects by patient reports or laboratory analysis.

    In plain wordsIn adults with schizophrenia, nose-spray oxytocin caused no adverse effects in patient reports or laboratory tests.

    Peptide
    Oxytocin
    Outcome
    No significant changeAdverse effects and laboratory safety
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    titrated to 40 IU twice a day · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Oxytocin was well tolerated and produced no adverse effects based upon patient reports or laboratory analysis.
    2 context sentences
    Summary · context
    Nineteen schizophrenia patients with residual symptoms despite being on a stable dose of at least one antipsychotic were enrolled in a randomized, double-blind, crossover study.
    Summary · context
    They received 3 weeks of daily intranasal oxytocin (titrated to 40 IU twice a day) and placebo adjunctive to their antipsychotics.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 completed · 1 stopped early · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01517360

Pharmacological Approach to Improve the Outcome of Social Cognition Training

VA Greater Los Angeles Healthcare Systemn = 27Jan 2012 to Feb 2013

Schizophrenia

Trial pageClinicalTrials.govUpdated 29 Mar 2013
CompletedNot applicableResults postedNCT01312272

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

VA Greater Los Angeles Healthcare Systemn = 24Apr 2011 to Aug 2012

Schizophrenia

Trial pageClinicalTrials.govUpdated 2 May 2014
TerminatedNot applicableResults postedNCT00506909

Oxytocin Add on Study for Stable Schizophrenic Patients

David Feifeln = 21Mar 2008 to Mar 2014

Schizophrenia

Trial pageClinicalTrials.govUpdated 25 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.